TCGA-E2-A56Z-01A-12R-A29R-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 8
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- DNA_REPAIR+0.360
- PANCREAS_BETA_CELLS+0.240
- INTERFERON_ALPHA_RESPONSE+0.150
- OXIDATIVE_PHOSPHORYLATION+0.140
- E2F_TARGETS+0.070
- PEROXISOME+0.070
- UV_RESPONSE_UP+0.070
- ESTROGEN_RESPONSE_LATE+0.060
- BILE_ACID_METABOLISM+0.020
- SPERMATOGENESIS+0.020
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.430
- UV_RESPONSE_DN-0.420
- INFLAMMATORY_RESPONSE-0.390
- MITOTIC_SPINDLE-0.370
- ALLOGRAFT_REJECTION-0.360
- IL6_JAK_STAT3_SIGNALING-0.360
- KRAS_SIGNALING_UP-0.350
- CHOLESTEROL_HOMEOSTASIS-0.320
- TNFA_SIGNALING_VIA_NFKB-0.320
- APICAL_JUNCTION-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-XF-AAN1-01A-31R-A42T-07 | — | — | 0.848 |
| 2 | TCGA-E9-A3HO-01A-11R-A213-07 | — | B | 0.832 |
| 3 | SRR5088826 | — | — | 0.816 |
| 4 | TCGA-BH-A0HN-01A-11R-A10U-07 | — | B | 0.814 |
| 5 | TCGA-AO-A0J3-01A-11R-A034-07 | — | B | 0.805 |
| 6 | MBCProject_0076_T1_RNA | — | B | 0.804 |
| 7 | 20110028.LumB | — | B | 0.799 |
| 8 | SRR35579800 | — | B | 0.796 |
| 9 | TCGA-PE-A5DC-01A-12R-A27Q-07 | — | B | 0.796 |
| 10 | TCGA-CN-A63U-01A-11R-A30B-07 | — | — | 0.794 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| DNA_REPAIR | 0.360 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.240 | Cobimetinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.150 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.140 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.070 | Inavolisib | — uncovered |
| PEROXISOME | 0.070 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.070 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.060 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.020 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.020 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.010 | Inavolisib | — uncovered |